From: Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)
Analysis
Sample Size
Lower boundary
Upper boundary
1
30
5
11
2
36
6
13
3
42
7
14
4
48
15
16